Pasithea Therapeutics Corp KTTA

$0.48 -0.01 (-2.68%)

Valuation

Market cap
16,343,000
Revenue TTM
$0
Net income TTM
$-20,430,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
59,900
Avg volume
208,782
Day's range
$0.47 – $0.51
Shares out
33,414,000
Stochastic %K
31%
Beta
0.34
Analysts
Sell
Price target
$3.00

Price

Company profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven...

Show more

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Industry
Biotechnology
Sector
Healthcare
Phone
786 977 3380
Website
https://www.pasithea.com
Address
1111 Lincoln Road, Suite 500, Miami Beach, United States

Latest news

Stocktwits

NVDAMillionaire Oct 2, 11:07 PM
$KTTA Brilliant piece that captures KTTA's situation perfectly. So if you want to update your understanding of KTTA or get to know KTTA better, this is essential reading. https://everyticker.com/quote/KTTA/analysis/pas-4-s-best-in-class-potential-meets-a-micro-cap-biotech-s-final-exam-the-ktta-investment-thesis-nasdaq-ktta
0 replies
focafoca99 Sep 9, 8:43 PM
$KTTA ratified its auditor appointment and approved a reverse stock split at its annual meeting.
0 replies
Risky_Behavoir Sep 8, 3:32 PM
$KTTA reverse split coming. Get out while you can!
0 replies
focafoca99 Aug 21, 9:16 PM
$KTTA received a 180-day Nasdaq extension to regain $1 minimum bid price compliance.
0 replies
TI7812 Aug 21, 4:16 PM
$KTTA taking a flyer, sized that if it goes to zero, no problem. Looked at the chart, then asked Claude these questions: pasted the text of this PR https://seekingalpha.com/pr/20567808-pasithea-therapeutics-announces-positive-interim-phase-1-advanced-cancer-study-data and prompted Claude with: do a analyst evaluation of the risk reward to buying this stock, ticker KTTA. HC Wainwright started coverage in June 2026, PT of $3.00. I noticed some big biotech hedge funds are taking a flyer on it as of 6/30/26 SEC filing, e.g., Opaleye Mgmt w/ 2m shares (that's like a loose change you drop in panhandler paper cup) explain the trial and the cancers being treated (stage #, biology it attacks,), TAM what is this about "No events of retinal or cardiac toxicity" what do the eyes have to do with this?
0 replies
Mino2103 Aug 18, 8:22 PM
$KTTA
0 replies
UtahSUV Aug 3, 3:41 PM
$KTTA my daily fuck you to this scam
1 replies
UtahSUV Aug 1, 6:48 AM
$KTTA what a POS
0 replies